Bloodstream Infections - From Threats to Solutions
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/11/2026
- Wall Street ends higher as investors turn to earnings season
- Oil prices settle lower on hopes for smoother shipping in Strait of Hormuz
- The real reason Meta shares are surging has nothing to do with its new AI model
- Stifel lifts Shopify to Buy, sees agentic commerce as next growth catalyst
- Delta Air Lines stock climbs on earnings beat and strong guidance
- Almonty Industries (ALM) PT Raised to $33 at DA Davidson
- JPMorgan analysts name top short ideas for third quarter 2026
- The real reason Meta shares are surging has nothing to do with its new AI model
- AppLovin gains market share among e-commerce advertisers
- Wall Street ends higher as investors turn to earnings season
EF Hutton Starts Citius Pharmaceuticals (CTXR) at Buy
July 15, 2024 9:35 AM EDTEF Hutton analyst Jason Kolbert initiates coverage on Citius Pharmaceuticals (NASDAQ: CTXR) with a Buy rating and a price target of $6.00.
The analyst comments "Low-Risk and High-Reward. Citius has two late-stage therapeutics, Mino-Lok (MLT) and LYMPHIR. Both products have demonstrated efficacy and safety and are in the final stages of the approval process.... More
